

QUINAZOLINE DERIVATIVEPatent Number: EP0726267, A4, B1

Publication date: 1996-08-14

Inventor(s): MORIYAMA TAKAHIRO (JP); NONAKA HIROMI (JP); KARASAWA AKIRA (JP); OKAMURA YUKO (JP); TAKAI HARUKI (JP); YAO KOZO (JP); FUJIWARA SHIGEKI (JP)

Applicant(s):: KYOWA HAKKO KOGYO KK (JP)

Requested Patent: US5948784

Application Number: EP19950929231 19950825

Priority Number (s): WO1995JP01694 19950825; JP19940202018 19940826

IPC Classification: C07D401/14 ; A61K31/55 ; A61K31/505

EC Classification: C07D401/14, C07D401/14REquivalents: AU3265595, AU689304, CA2174854, CN1043991B, CN1134150, DE69519469D, ES2153491T, FI961758, JP9165385, NO961601, NZ291506, WO9606841**Abstract**

Disclosed are quinazoline derivatives represented by formula (I): wherein R<1> represents hydrogen, lower alkyl, alkenyl, or aralkyl; R<2>, R<3>, R<4>, and R<5> represent hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, or the like; R<6>, R<7>, R<8>, and R<9> represent hydrogen, lower alkyl, lower alkoxy, aralkyloxy, or the like, or any adjoining two of them are combined to form methylenedioxy or the like; R<10> represents hydrogen, lower alkyl, or the like; R<11> and R<12> represent hydrogen, lower alkyl, cycloalkyl, phenyl, or aralkyl, or R<11> and R<12> are combined together with N to form a heterocyclic group; and n represents 0, 1 or 2, and pharmaceutically acceptable salts thereof. These compounds have adenosine uptake inhibitory activity and are useful for the protection of myocardium and for the prevention or treatment of inflammation such as leg and foot edema.

Data supplied from the **esp@cenet** database - I2

— Please see exhibit 23 —